3027 Bern, ch
+41 (58) 8528-517
FDA assigns PDUFA Date for Injectafer® NDA
The FDA has assigned 3 August 2012 as the Prescription Drug User Fee Act (PDUFA) target action date to complete its review of the New Drug Application (NDA) for Injectafer® for the treatment of iron deficiency anaemia.
The PDUFA action date is a target date for the FDA to complete its review. The FDA could respond sooner or extend the action date as the review and discussions progress.
For more information, please visit: http://www.galenica.com/en/medien/medienmitteilungen/2011/20111013_626568872_meldung.php
Iron Deficiency Anemia (IDA) is a state in which iron stores are inadequate for normal blood formation, as the iron requirements exceed the supply. In severe cases red cells in a patient with IDA are both microcytic (small) and hypochromic (pale), and values for mean corpuscular volume (MCV) and mean corpuscular Hb concentration (MCHC) are characteristically reduced. According to the World Health Organization (WHO) it is estimated that about 700 million people have iron deficiency anaemia (IDA). [Source: World Health Organization. Preventing and controlling Iron Deficiency Anaemia through primary health care. Available at: http://www.who.int/nutrition/publications/micronutrients/anaemia_iron_deficiency/ida_preventng_control_primary_healthcare.pdf]
Injectafer® is an innovative non-dextran intravenous iron (i.v.) replacement therapy discovered and developed by Vifor Pharma, a company of the Galenica Group. Ferric carboxymaltose is the active pharmaceutical ingredient of Injectafer®. To date, Ferinject® (brand name of Injectafer® outside the US) has gained marketing authorisation in 37 countries worldwide for the treatment of iron deficiency where oral iron is ineffective or cannot be used. In many countries, intravenous iron replacement products are primarily used to treat dialysis patients. However, iron deficiency is also a complication of many other illnesses. Vifor Pharma is evaluating new opportunities in the treatment of iron deficiency with Ferinject® in different therapeutic areas. Further trials with Ferinject® in chronic kidney disease (CKD), oncology (anaemia in cancer patients), cardiology (chronic heart failure), patient blood management and gynaecology are ongoing.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.